ACT001
Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)
Phase 1Active
Key Facts
Indication
Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)
Phase
Phase 1
Status
Active
Company
About Accendatech
Accendatech USA Inc., founded in 2017, is a clinical-stage biotech developing ACT001, a drug candidate for treating glioblastoma and DIPG, a rare pediatric brain tumor. The company has completed Phase 1 clinical trials for ACT001 and is advancing its development. As a subsidiary of the publicly-traded Accendatech Co. Ltd. in China, it leverages its parent company's research while establishing a U.S. operational base in Houston, Texas, to drive clinical development and partnerships.
View full company profile